ACAD — ACADIA Pharmaceuticals Inc. stock price, charts and financials

QT64ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.15
+1.54+6.01%
OverviewShort InterestFilings
ACADQT64ACADIA Pharmaceuticals Inc.·NASDAQ
27.15+6.01%
Earnings
Up 6.0% — Reported earnings — EPS missed by 60%, revenue missed by 4%.
High confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
DNTH+4.13%$110.40CELC+5.44%$92.49MANE+5.29%$107.28DFTX+1.27%$42.32CAI-1.35%$16.10ELVN+5.29%$61.11EWTX+16.49%$44.71DYN+2.89%$25.97
Snapshot
Index-P/E11.64EPS (ttm)2.20Insider Own46.92%Shs Outstand171.24MPerf Week0.87%
Market Cap4.39BForward P/E30.72EPS next Y0.83Insider Trans-0.10%Shs Float169.05MPerf Month-1.39%
Enterprise Value3.59BPEG0.20EPS next Q-Inst Own-Short Float6.52%Perf Quarter16.67%
Income377.00MP/S4.00EPS this Y-82.42%Inst Trans-Short Ratio6.50Perf Half Y1.91%
Sales1.10BP/B3.51EPS next Y115.55%ROA23.40%Short Interest11.03MPerf YTD-4.12%
Book/sh7.29P/C5.15EPS next 5Y57.44%ROE35.65%52W High30.05 -9.66%Perf Year7.47%
Cash/sh4.97P/FCF20.85EPS past 3/5Y-ROIC6.17%52W Low20.87 30.07%Perf 3Y-11.75%
Dividend Est.-EV/EBITDA28.23Sales past 3/5Y27.52% 19.39%Gross Margin91.47%Volatility2.88% 2.94%Perf 5Y20.29%
Dividend TTM-EV/Sales3.27EPS Y/Y TTM61.76%Oper. Margin7.39%ATR (14)0.81Perf 10Y-29.93%
Dividend Ex-Date-Quick Ratio3.48Sales Y/Y TTM14.41%Profit Margin34.30%RSI (14)55.25Recom2.32
Dividend Gr. 3/5Y-Current Ratio3.59EPS Q/Q-81.82%SMA20-0.33%Beta0.84Target Price32.06
Payout0.00%Debt/Eq0.04Sales Q/Q9.84%SMA507.93%Rel Volume0.85Prev Close25.61
Employees798LT Debt/Eq0.03EarningsAug 04SMA2008.24%Avg Volume1.61MPrice27.15
IPO DateMay 27, 2004Option/ShortYes / YesEPS/Sales Surpr.-60.40% -4.34%Net Debt/EBITDA-1.82Volume1,368,055Change6.01%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-29-26ReiteratedRaymond JamesOutperform$15
Jul-21-26ReiteratedBMO CapitalOutperform$31 → $36
Jul-07-26ReiteratedRBC CapitalOutperform$31 → $36
Jun-29-26ReiteratedDeutsche BankBuy$32 → $37
Jun-29-26ReiteratedCanaccord GenuityBuy$33 → $36
Mar-25-26UpgradeB of A SecuritiesNeutral → Buy
Mar-02-26ReiteratedWilliam Blair$29
Feb-23-26InitiatedWolfe ResearchOutperform$33
Feb-23-26UpgradeMizuhoNeutral → Outperform$29 → $35
Feb-03-26ReiteratedRBC CapitalOutperform$21 → $31
Latest News
Aug-04-26
Aug-04-2606:41PM
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimateszacks.com
06:04PM
ACADIA Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Aug-01-26
Aug-01-2603:50AM
Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACADdefenseworld.net
Jul-30-26
Jul-30-2605:57PM
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conferencebusinesswire.com
12:41PM
HRMY or ACAD: Which Is the Better Value Stock Right Now?zacks.com
Jul-28-26
Jul-28-2611:06AM
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?zacks.com
Jul-27-26
Jul-27-2601:41PM
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?zacks.com
09:27AM
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readoutseekingalpha.com
Jul-23-26
Jul-23-2610:55AM
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to Tradezacks.com
Jul-22-26
Jul-22-2603:40AM
ACADIA Pharmaceuticals Inc. $ACAD Shares Acquired by Bessemer Group Inc.defenseworld.net
Jul-21-26
Jul-21-2601:26PM
Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha
11:50AM
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidatezacks.com
03:08AM
Allspring Global Investments Holdings LLC Buys 296,042 Shares of ACADIA Pharmaceuticals Inc. $ACADdefenseworld.net
Jul-20-26
Jul-20-2609:05AM
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosisbusinesswire.com
Company

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,0961,072958726517484442339224
Cost of Goods Sold Incl. D&A948982461019212018
Gross Profit1,002983876681507465421319205
Selling, General and Administrative Excl. Other594549488402369396389326266
Research and Development328329303352362239319240187
Other Operating Expense-20-146000000
Operating Income80105231-73-224-170-287-247-247
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)353427221036124
Net Income Before Taxes115139258-51-213-168-281-234-244
Income Taxes-260-252321030111
Consolidated Net Income377391226-61-216-168-282-235-245
Net Income From Continuing Operations377391226-61-216-168-282-235-245
Net Income377391226-61-216-168-282-235-245
EPS (Recurring)2.232.321.37-0.37-1.34-1.05-1.79-1.60-1.94
EPS (Basic, Before Extraordinaries)2.232.321.37-0.37-1.34-1.05-1.79-1.60-1.94
EPS (Diluted)2.202.291.36-0.37-1.34-1.05-1.79-1.60-1.94
EBITDA127151100-45-211-164-284-244-244
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio12.3411.6613.49——————
Price To Sales Ratio4.244.213.187.074.997.7218.9918.559.17
Gross Margin91.4291.7091.4493.8098.0796.0795.2594.1091.52
Operating Margin7.309.7924.11-10.06-43.33-35.12-64.93-72.86-110.27
Net Margin34.4036.4723.59-8.40-41.78-34.71-63.80-69.32-109.38
Shares Outstanding171169166164162160157147127
Market Capitalization4,6434,5143,0465,1352,5793,7348,3936,2892,054
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.26$26.66$24.06$21.46$18.86● Close Price0.00M0.25M0.51M0.76M1.01MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 30 '26Sale26.1316,558432,66318,994Jul 31
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 29 '26Option Exercise0.0032,272035,552Jul 31
Kihara JamesPRINCIPAL ACCOUNTING OFFICERJun 26 '26Sale26.0811,421297,91213,088Jun 29
Brege LauraDirectorMay 29 '26Option Exercise0.008,107023,202Jun 01
Poole JonathanDirectorMay 29 '26Option Exercise0.002,01002,010Jun 01
Daly James MDirectorMay 29 '26Option Exercise0.008,107012,148Jun 01
GAROFALO ELIZABETH A.DirectorMay 29 '26Option Exercise0.008,107033,489Jun 01
HARRIGAN EDMUNDDirectorMay 29 '26Option Exercise0.008,107043,148Jun 01
Ndu AdoraDirectorMay 29 '26Option Exercise0.008,107032,908Jun 01
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 26 '26Sale21.185,401114,39324,509May 27
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 04 '26Sale21.791,33229,02429,129May 05
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 04 '26Sale21.793,50676,39666,145May 05
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 01 '26Option Exercise0.002,596030,461May 05
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 01 '26Option Exercise0.006,815069,651May 05
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERApr 07 '26Sale22.202,70960,14062,836Apr 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.